The Promise of Bispecific Antibodies

The redirection of T cells against tumors holds significant promise for the treatment of cancer. Two main approaches for T-cell redirection involve their genetic modification with chimeric antigen receptors (CAR) or the use of bispecific antibodies that can bind to two different antigens simultaneously. On this episode of CANCER BUZZ, learn about these promising breakthroughs, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.  Guest: Firas El Chaer, MD, Assistant Professor of Medicine, Department of Hematology and Oncology, University of Virginia, Emily Couric Clinical Cancer Center Related Content: Preparing Community Providers for Bispecific Antibodies How Targeted Therapies Are Affecting the Cancer Care Team: A Conversation with Dr. Firas El Chaer CAR T-Cell Therapy Gave Me Back My Life CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment, American Association for Cancer Research Bispecific Antibodies: Success and Challenges, The ASCO Post The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.